Discover how targeting S100A1 protein can overcome immunotherapy resistance and enhance anti-PD-1 efficacy in cancer treatment.
Discover how the CIVO platform and TAK-981 are revolutionizing cancer drug development by providing real-time insights into tumor immune responses.
Discover how TMEM176A and TMEM176B proteins regulate dendritic cell maturation and their implications for cancer, autoimmune diseases, and immunotherapy.
Discover how Cbl-b deficiency makes T cells resistant to PD-L1-mediated inhibition and its implications for cancer immunotherapy.
How dual-functional nanoplatforms are transforming osteosarcoma treatment by modulating the tumor microenvironment and activating immune responses.